Treatment of cutaneous neurogenic inflammation
AssigneeAstion Pharma A/S
InventorMorten Sloth Weidner
Life of this patent
Estimating the term…
Abstract
The glyceryl fatty acid monoester of octanoic acid, i.e. 1-glyceryl monocaprylate has, unlike other glyceryl fatty acid esters, such as 1-glyceryl monocaprate, been shown to inhibit cutaneous neurogenic inflammation. Therefore, this invention features uses and dermatological compositions of 1-glyceryl monocaprylate or analogues thereof for the treatment of cutaneous neurogenic inflammation, such as pruritus, pruritic skin disorders and seborrheic dermatitis, even without the need of co-administering other anti-inflammatory agents.
Claims33
A method of treating cutaneous neurogenic inflammation, comprising administering a dermatological composition comprising a therapeutically effective amount of 1-glyceryl monocaprylate or an analogue thereof to the affected skin areas of a subject in need thereof.
A method of treating a skin condition or skin disorder associated with cutaneous neurogenic inflammation, comprising administering a dermatological composition comprising a therapeutically effective amount of 1-glyceryl monocaprylate or an analogue thereof to the affected skin areas of a subject in need thereof.
A dermatological composition formulated for the application to skin for the local treatment of a skin disorder, the dermatological composition comprises 1-glyceryl monocaprylate or an analogue thereof as the therapeutically active ingredient and further comprises a dermatologically acceptable vehicle.
The dermatological composition according to claim 33, wherein the anti-fungal agent is selected from the group consisting of miconazole, econazole, terconazole, saperconazole, itraconazole, butaconazole, clotrimazole, tioconazole, fluconazole and ketoconazole, vericonazole, fenticonazole, sertaconazole, posaconazole, bifonazole, oxiconazole, sulconazole, elubiol, vorconazole, isoconazole, flutrimazole, allylamine, ternafine, naftifine, amorolfine, butenafine, ciclopirox, griseofulvin, undecyclenic acid, haloprogin, tolnaftate, nystatin, iodine, rilopirox, BAY 108888, purpuromycin and their pharmaceutically acceptable salts.
Dependencies are inferred from the claim text.